READ BEFORE USING

DBX® Demineralized Bone Matrix Putty

DONATED HUMAN TISSUE


DESCRIPTION
DBX Demineralized Bone Matrix Putty is processed human bone that has been demineralized and combined with sodium hyaluronate, which is a naturally derived material not of animal origin that is both biocompatible and biodegradable. The combination of demineralized bone and sodium hyaluronate results in a putty-like consistency for ease and flexibility of use during surgical application.

OSTEOINDUCTIVE POTENTIAL
DBX Demineralized Bone Matrix Putty is osteoconductive and has been shown to have osteoinductive potential in an athymic mouse model. Every lot of final DBX Putty product is tested in vivo or in an alkaline phosphatase assay, which has been shown to have a positive correlation with the athymic mouse model, to ensure the osteoinductive potential of the final product. Standard testing performed in vivo or by the alkaline phosphatase assay must prove positive for lot release. It is unknown how the osteoinductive potential measured in vivo or by the alkaline phosphatase assay, will correlate with clinical performance in human subjects.

INDICATIONS FOR USE
DBX Putty is intended for use as a Demineralized Bone Matrix for voids or gaps that are not intrinsic to the stability of the bony structure. DBX Putty is indicated for treatment of surgically created osseous defects or osseous defects created from traumatic injury.

DBX Putty can be used as follows:
- Mandibular reconstruction
- Repair of traumatic defects of the alveolar ridge, excluding maxillary and mandibular fracture
- Filling resection defects in benign cysts, or other osseous defects in the alveolar ridge wall
- Filling of cystic defect
- Filling of lesions or periodontal origin
- Filling of defects of endodontic origin

DBX Putty can be used as an extender in the spine, pelvis, and extremities with autograft or allograft. DBX Putty can be used with bone marrow aspirate. DBX Putty is for single patient use only.

CONTRAINDICATIONS
DBX Putty is NOT intended to provide structural support of the bone during the healing process. DBX Putty is also contraindicated in the following circumstances:
- Incomplete skull growth
- Severe vascular or neurological disease
- Fever
- Uncontrolled diabetes
- Severe degenerative bone disease
- Pregnancy
- Hypercalcemia
- Renal-compromised patients
- History of or active Pott’s disease
- Osteomyelitis at the surgical site
- Sepsis in or around the surgical site
- Inability to cooperate with and/or comprehend post-operative instructions

ADVERSE EFFECTS
Possible adverse effects of using DBX Putty include, but are not limited to:
- Potential loss of contour of skull
- Infection of soft tissue and/or bone (osteomyelitis)
- Fever
- Deformity of the bone at the site
- Incomplete bone ingrowth, delayed union or non-union
- Hypercalcemia or transient hypercalcemia
- Fracture of the newly formed bone
- Disease transmission and undesirable immune response

Within the United States: Adverse outcomes attributable to the tissue must be promptly reported to MTF. Outside of the United States: Adverse outcomes attributable to the tissue must be promptly reported to your local representative.

DO NOT STERILIZE. DBX Demineralized Bone Matrix Putty may extrude into facial soft tissue and the effect of extrusion in cranial applications, due to the lack of soft tissue, has not been investigated.

Trace amounts of Gentamicin antibiotic, Polysorbate-80, Ethanol, Methanol, Isopropanol and Hydrogen Peroxide may be present. Caution should be exercised if the patient is allergic to any of these substances. NOTE: No β-lactam antibiotics are used during the processing of tissue in DBX Putty products.

Extensive medical screening procedures have been used in the selection of all tissue donors for MTF (please see Donor Screening and Testing). Transmission of infectious diseases such as HIV or hepatitis, as well as a theoretical risk of the Creutzfeldt-Jakob (CJD) agent, may occur in spite of careful donor selection and serological testing.

Closed suction or drainage is recommended to prevent fluid accumulation in the wound.

DEVICE INFORMATION
DBX Putty is composed of Demineralized Bone Matrix and sodium hyaluronate. The demineralized bone allograft in this product is prepared from tissue procured from a deceased donor using aseptic surgical techniques. The bone used in DBX Putty is cortical bone. These tissues were treated with Gentamicin and were cleaned using 70% ethanol and washed with purified water. The bone was demineralized using hydrochloric acid. The demineralized bone was then lyophilized to a controlled moisture content. The demineralized bone was combined with sterile-filtered sodium hyaluronate prior to packaging.

Sodium hyaluronate is a naturally derived material that is biocompatible and biodegradable. The sodium hyaluronate is mixed in a phosphate buffered saline and is added to the demineralized bone to aid in maintaining physiological pH as well to improve the handling characteristics of demineralized bone.

CAUTIONS

Some tissues are treated with low-dose gamma radiation. For these tissues the container label will state, “Treated with Gamma Radiation.” Samples from each donor lot of DBX Putty were tested and showed no evidence of microbial growth, complying with the requirements of USP <71> Sterility Tests.
INSTRUCTIONS FOR USE
DBX Putty is packaged in a glass syringe and must be extruded into a sterile basin, not directly into the operative site. THE SYRINGE IS NOT AN APPLICATOR. Care should be taken to apply gentle, even force to the plunger when extruding DBX Putty from the syringe. Extreme force applied to the plunger may cause the glass syringe to break.

DBX Putty can be used alone or mixed with autogenous or allograft bone (1:1 ratio by volume), or with bone marrow aspirate (2.0 mL/2.8 g of DBX Putty or 2.0 cc/2.8 cc of DBX Putty).

NOTE: This allograft has been aseptically packaged into sterilized packaging components.

To make ready for use, open the package using aseptic/sterile techniques.

Instructions for Opening the Package:
1. Peel back lid of outer tray.
2. Pass inner tray to sterile field.
3. Peel back lid of inner tray.
4. Remove syringe from inner tray.
5. Remove protective cap from end of syringe.
6. Extrude DBX Putty into a sterile basin.
7. Shape and use DBX Putty as per surgeon’s preference.

Dispose of excess or unused tissue and all packaging that has been in contact with the tissue in accordance with recognized procedures for discarding regulated medical waste materials.

DONOR SCREENING & TESTING
Prior to donation, the donor’s medical/social history is screened for medical conditions or disease processes that would contraindicate the donation of tissues in accordance with current policies and procedures approved by the MTF Medical Board of Trustees.

Donor blood samples taken at the time of recovery were tested by a CLIA licensed facility for:
- Hepatitis B surface antigen
- HIV-1/2 antibody
- Hepatitis B core antibody
- Syphilis
- Hepatitis C antibody
- HIV-1 (NAT)
- HCV (NAT)

The results of all serological testing were negative. This allograft tissue has been determined to be suitable for transplantation.

The infectious disease test results, consent, current donor medical history interview, physical assessment, available relevant medical records to include previous medical history, laboratory test results, autopsy and coroner reports, if performed, and information obtained from any source or records which may pertain to donor suitability, have been evaluated by an MTF physician and are sufficient to indicate that donor suitability criteria current at the time of procurement, have been met. This tissue is suitable for transplantation. The donor suitability criteria used to screen this donor are in compliance with the FDA regulations published in 21 CFR Part 1271 Human Cells, Tissues, and Cellular and Tissue Based Products, as applicable.

All procedures for donor screening, serologic and microbiologic testing meet or exceed current standards established by the American Association of Tissue Banks.

VIRAL CLEARANCE AND INACTIVATION
A panel of model potential human viruses representing various virus types, sizes, shapes and genomes were evaluated. The viral inactivation testing demonstrated suitable viral inactivation potential of the processing method for a wide spectrum of potential human viruses. The DBX Putty process further reduces the risk of viral contamination beyond donor testing and screening procedures.

PACKAGING & LABELING
DBX Putty is aseptically packaged in a sterilized syringe. The syringe containing DBX Putty is inside two plastic trays, each sealed with foil lids. The outer tray is labeled and then put in a box.

This allograft must not be used under any of the following circumstances:
- If the container seal is damaged or not intact or has any physical damage;
- If the container label or identifying bar code is severely damaged, not legible or is missing; or
- If the expiration date shown on the container label has passed.

STORAGE
Store DBX Putty at ambient temperature. No refrigeration or freezing is required. It is the responsibility of the transplant facility or clinician to maintain the tissue intended for transplantation in the appropriate recommended storage conditions prior to transplant.

PATIENT RECORD
Tissue recipient records must be maintained by the consignee and transplant facility for the purpose of tracing tissue post-transplantation. This will allow MTF to facilitate the investigation of actual or suspected transmission of communicable disease and take appropriate and timely corrective action. A TissueTrace® Tracking Form and peel-off stickers have been included with each package of tissue. The serial number and the tissue description have been preprinted on the peel-off stickers. Please record the patient ID, name and address of the transplant facility, allograft tissue information (using the peel-off stickers), and comments regarding the use of the tissue on the TissueTrace Tracking Form. Alternatively a system for electronic submission may be used. Within the United States: Once completed, the bottom page of the form should be returned to MTF using the self-addressed, postage paid mailer. Copies of this information should be retained by the transplant facility for future reference.

Outside of the United States: Once completed, the bottom page of the form should be returned to the local allograft representative or provider. Copies of this information should be retained by the hospital for future reference.

Reference: Current MTF policies and procedures in compliance with current FDA, AABB and other regulatory requirements.

Definitions of Label Symbols

CAUTION: Federal (US) law restricts this device to sale, distribution and use by or on the order of a physician.

This tissue form is covered by the following US Patents: US 6,030,635; US 6,437,018; US 6,911,212; US 7,019,192

DBX® is a registered trademark of MTF.

MTF Musculoskeletal Transplant Foundation® is a registered trademark of the Musculoskeletal Transplant Foundation, Edison, NJ USA.

PI - 64, Rev 2, 11/2011